SBI Okasan Asset Management Co.Ltd. Purchases Shares of 9,190 Abbott Laboratories $ABT

SBI Okasan Asset Management Co.Ltd. purchased a new stake in Abbott Laboratories (NYSE:ABT) in the 4th quarter, Holdings Channel.com reports. The fund purchased 9,190 shares of the healthcare product maker’s stock, valued at approximately $1,145,000.

Other institutional investors also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at $25,000. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories during the fourth quarter worth approximately $27,000. Cloud Capital Management LLC purchased a new position in Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories during the third quarter worth approximately $31,000. Finally, Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories during the third quarter worth approximately $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 3,055 shares of company stock worth $353,097 in the last quarter. 0.46% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ABT. Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Leerink Partners cut their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a research note on Monday, April 27th. Piper Sandler cut their price target on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Sanford C. Bernstein cut their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $119.09.

Abbott Laboratories Stock Up 0.6%

Shares of NYSE ABT opened at $86.19 on Friday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a market cap of $150.13 billion, a P/E ratio of 24.14, a P/E/G ratio of 1.43 and a beta of 0.65. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a fifty day moving average price of $94.92 and a 200 day moving average price of $110.87.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the firm earned $1.09 EPS. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott secured CE Mark approval in Europe for Libre Duo, the world’s first dual glucose-ketone sensing technology for diabetes care, which could broaden its addressable market and strengthen its diabetes device franchise. Article Title
• Positive Sentiment: The American Cancer Society reaffirmed Abbott’s noninvasive colorectal cancer screening products, Cologuard and Cologuard Plus, as preferred options for average-risk adults, supporting demand for the company’s screening portfolio. Article Title
• Positive Sentiment: Abbott also won FDA and EU clearance for its AI-powered Ultreon 3.0 software, which helps guide artery stent placement and could support growth in its cardiovascular business. Article Title
• Neutral Sentiment: Analyst-focused articles reiterated that Wall Street remains broadly bullish on Abbott, and Goldman Sachs maintained a Buy rating even after trimming its price target to $113 from $121. Article Title
• Neutral Sentiment: Commentary on Abbott’s diagnostics unit pointed to a mixed quarter, with Core Lab growth offset by China weakness and softer respiratory testing demand, suggesting uneven near-term performance in the segment. Article Title
• Negative Sentiment: Some market coverage noted that Abbott’s shares fell in a recent session despite a broader market uptick, reflecting lingering pressure even as fundamental news flow turns more favorable. Article Title

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.